CCX354 / Amgen - LARVOL DELTA

Identification of potential drug targets for vascular dementia and carotid plaques by analyzing underlying molecular signatures shared by them. (PubMed, Front Aging Neurosci) - "The drug-gene interaction analysis showed that four drugs (avacopan, CCX354, BMS-817399, and ASK-8007) could be potential drugs for VaD and carotid atherosclerotic plaques treatment. Collectively, these findings indicated that inflammatory and immune-related processes be a crucial common pathophysiological mechanism shared by VaD and carotid plaques. This study might provide new insights into common molecular mechanisms between VaD and carotid plaques and potential targets for the treatment."

Journal • Alzheimer's Disease • Atherosclerosis • Cardiovascular • CNS Disorders • Dementia • Dyslipidemia • Immunology • CD4

ChemoCentryx announces peer-reviewed publication of positive phase 2 clinical data with CCX354, a novel inhibitor of chemokine receptor CCR1 in patients with rheumatoid arthritis (Chemocentryx, EULAR 2012) - P2, N=160; CCX354 was generally well tolerated by patients with RA; ACR20 response at week 12 was 56% in patients receiving 200mg CCX354 once daily, compared to 44% in patients receiving 100mg twice daily and 30% in patients receiving placebo; ACR20 is a standard measure of improvement in tender and swollen joint counts; The difference between 200mg once daily & placebo was statistically significant (p=0.014)

P2 data • Rheumatoid Arthritis

ChemoCentryx announces peer-reviewed publication of positive phase 2 clinical data with CCX354, a novel inhibitor of chemokine receptor CCR1 in patients with rheumatoid arthritis (Chemocentryx, EULAR 2012) - P2, N=160; CCX354 was generally well tolerated by patients with RA; ACR20 response at week 12 was 56% in patients receiving 200mg CCX354 once daily, compared to 44% in patients receiving 100mg twice daily and 30% in patients receiving placebo; ACR20 is a standard measure of improvement in tender and swollen joint counts; The difference between 200mg once daily & placebo was statistically significant (p=0.014)

P2 data • Rheumatoid Arthritis

ChemoCentryx reports clinical efficacy for CCX354, a novel CCR1 inhibitor in a phase II study in patients with rheumatoid arthritis (Chemocentryx) - P2, N=160; CARAT-2; ACR20 response at week 12 was 56% in pts receiving 200mg CCX354 once daily compared to 44% in pts receiving 100mg twice daily, & 30% in pts receiving placebo; The difference between 200mg once daily & placebo was statistically significant (p=0.014); The decrease in CRP, a marker of inflammation, was statistically significant in the 200mg QD group compared to placebo at week 12 (p=0.023)

P2 data • Rheumatoid Arthritis

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial (Ann Rheum Dis) - P2, N=160; CCX354-C was generally well tolerated by study subjects; The ACR20 response at week 12 was 39% in the placebo group, 43% in the 100mg twice daily group (4.5; p=0.62) & 52% in the 200mg once daily group (13.0; p=0.17) in the intention-to-treat population

P2 data • Rheumatoid Arthritis